The Chemours Company (CC) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales were $1.54 billion, down 6% year-over-year, with net income of $70 million, rebounding from a $376 million loss in Q2 2023.

• Adjusted EBITDA was $206 million, a 36% decrease from $324 million in the prior-year quarter.

• All segments experienced lower pricing, but Opteon refrigerants saw double-digit growth and TT volumes rebounded despite Altamira disruptions.

• The company completed a leadership transition with a new CFO and advanced sustainability initiatives, including SBTi approval and its seventh annual sustainability report.

• Significant progress was made on internal control remediation following the Audit Committee Internal Review.

Financial highlights

• Net sales declined 6% year-over-year to $1.54 billion, but increased 14% sequentially from Q1 2024.

• Adjusted EBITDA fell to $206 million from $324 million year-over-year, but rose from $193 million sequentially.

• Adjusted net income was $57 million ($0.38 per diluted share), down from $167 million ($1.10 per share) in the prior year.

• Operating cash outflow was $620 million in Q2, mainly due to a $606 million settlement fund payment.

• Capital expenditures were $73 million, and $38 million was paid in dividends in Q2.

Outlook and guidance

• Q3 2024 is expected to see a sequential low- to mid-single-digit decline in net sales and a high single-digit decline in adjusted EBITDA.

• TT segment will continue to be impacted by Altamira downtime, with one-time costs of $15–$20 million expected in Q3.

• Continued strong adoption of Opteon refrigerants and modest APM recovery are projected.

• No liquidity concerns anticipated for the remainder of 2024, with stable cash balances and working capital inflows expected.

• No additional share repurchases are anticipated; focus remains on growth investments, deleveraging, and legal/environmental obligations.